Biotech Iproteos has closed a round of funding valued at 1.5 M€

Teresa Tarragó, IRB Barcelona researcher, CEO and co-founder of Iproteos.
Teresa Tarragó, IRB Barcelona researcher, CEO and co-founder of Iproteos.

The newspaper “Expansión” highlights the round of funding valued at 1.5 M€ closed by the biotech Iproteos—co-founded by IRB Barcelona and the University of Barcelona—, based at the Barcelona Science Park. 

The biotech will set aside this capital for the completion of the regulatory preclinical phase of a first-in-class drug for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).